资讯

pharmaphorum

Could a Novo error set up early GLP-1 generics in Canada?

It has been reported that Novo Nordisk may have inadvertently allowed generics of its GLP-1 agonist semaglutide, the active ingredient in diabetes therapy Ozempic and ...